SK Bioscience said Turkey’s health authorities had granted its vaccine factory GMP certification, increasing the chance for self-developed vaccines to be exported.
On Friday, the company announced that Turkey’s Medicines and Medical Devices Authority renewed GMP certification for the vaccine facility, manufacturing process and quality control system of L House in Andong, North Gyeongsang Province.
The facility produces SK Bioscience’s trivalent and tetravalent influenza vaccine SKYCellflu, chickenpox vaccine SKYvaricella and shingles vaccine SKYZoster.
Renewal of GMP certification will lay the foundation for supplying SK Bioscience’s vaccines to 85 million people in Turkey‘s pharmaceutical market, SK Bioscience said.
In order to export pharmaceutical products to Turkey, the company must obtain a GMP certificate from the Turkish authorities.
SK Bioscience obtained the first Turkish GMP certification for L-House’s vaccine production facility in May 2019. Before the certification expired in early February, the company passed and successfully renewed the review.
With the renewed GMP certification, SK Bioscience plans to participate in the Turkish government’s international chickenpox vaccine tender, accelerate the export of four vaccines to Turkey, and expand the market in Europe and Asia.
However, the company has yet to release detailed plans for obtaining market approval in Turkey.
Ahn Jae-yong, CEO of SK Bioscience, said L-House has repeatedly received various international certifications to prove its technological strength and development/production capacity.
“Based on the trust we have built in the global market in the wake of Covid-19, we will continue to work with various global companies to progressively increase our market impact.”